CGRP 억제제 세계 시장 규모는 2024년 32억 9,000만 달러로 평가되었고, 예측 기간 동안 9.72%의 연평균 복합 성장률(CAGR)로 2030년에는 48억 7,000만 달러에 달할 것으로 예상됩니다.
CGRP(칼시토닌 유전자 관련 펩타이드) 억제제는 편두통 및 군발성 두통과 같은 쇠약해진 상태를 치료하고 완화하기 위해 고안된 새로운 약물 계열로, 세계 CGRP 억제제 시장은 제약 및 헬스케어 산업에서 역동적이고 빠르게 발전하고 있는 분야로 부상하고 있습니다. 이 시장은 전 세계 편두통 유병률 증가와 기존 치료 옵션의 제한적인 효과로 인해 상당한 성장과 혁신을 목격하고 있으며, 2024년 3월에 발표된 세계보건기구(WHO)의 논문에 따르면 2021년에는 전 세계 인구의 약 40%, 약 31억 명에 해당하는 사람들이 편두통 및 기타 두통 장애를 겪을 것으로 예상됩니다. 사람들이 편두통 및 기타 두통 장애를 경험하고 있습니다.
| 시장 개요 | |
|---|---|
| 예측 기간 | 2026-2030년 |
| 시장 규모 : 2024년 | 32억 9,000만 달러 |
| 시장 규모 : 2030년 | 48억 7,000만 달러 |
| CAGR : 2025-2030년 | 9.72% |
| 급성장 부문 | 경구 |
| 최대 시장 | 북미 |
세계 CGRP 억제제 시장 확대의 주요 촉진요인 중 하나는 전 세계 수백만 명의 사람들에게 영향을 미치는 편두통 발생률 증가입니다. 편두통은 견디기 힘든 고통뿐만 아니라 결근과 생산성 저하로 인한 경제적 부담도 큽니다. 이에 따라 제약회사들은 CGRP 억제제 연구개발에 많은 투자를 하고 있으며, 편두통 발작의 빈도와 중증도 감소에 큰 효과를 보이고 있습니다. 또한, 다양한 CGRP 억제제가 FDA의 승인을 받아 안전성과 유효성을 입증한 것도 시장 성장을 가속하고 있습니다. 이러한 승인은 의료진과 환자들 사이에서 CGRP 억제제가 널리 채택될 수 있는 길을 열어주었습니다. 그 결과, 여러 브랜드 의약품과 제네릭 의약품이 시장에 출시되어 환자에게 다양한 선택권을 제공함으로써 시장 확대에 기여하고 있습니다. 또한, 세계 CGRP 억제제 시장은 제약사들 간의 치열한 경쟁이 특징이며, 각 제약사들은 환자의 예후를 개선하기 위해 혁신적인 제형과 투여 방법을 개발하기 위해 끊임없이 노력하고 있습니다. 또한, 생명공학 및 신경과학의 발전은 편두통의 근본적인 메커니즘에 대한 이해를 촉진하여 보다 표적화되고 효과적인 CGRP 억제제 개발로 이어지고 있습니다.
편두통 및 군발성 두통의 유병률 증가
고가의 치료비와 접근성 문제
바이오시밀러와 제네릭 의약품의 부상
Global CGRP Inhibitor Market was valued at USD 3.29 Billion in 2024 and is expected to reach USD 4.87 Billion by 2030 with a CAGR of 9.72% during the forecast period. The Global CGRP Inhibitor Market has emerged as a dynamic and rapidly evolving sector within the pharmaceutical and healthcare industry. CGRP (Calcitonin Gene-Related Peptide) inhibitors represent a novel class of drugs designed to address and alleviate debilitating conditions such as migraines and cluster headaches. This market has witnessed substantial growth and innovation due to the increasing prevalence of migraine disorders worldwide and the limited effectiveness of existing treatment options. As per the World Health Organization (WHO) article published in March 2024, an estimated 40% of the global population, equivalent to approximately 3.1 billion individuals, experienced migraine and other headache disorders in 2021.
| Market Overview | |
|---|---|
| Forecast Period | 2026-2030 |
| Market Size 2024 | USD 3.29 Billion |
| Market Size 2030 | USD 4.87 Billion |
| CAGR 2025-2030 | 9.72% |
| Fastest Growing Segment | Oral |
| Largest Market | North America |
One of the key drivers behind the expansion of the Global CGRP Inhibitor Market is the rising incidence of migraines, affecting millions of people across the globe. Migraines not only result in excruciating pain but also lead to substantial economic burdens due to missed workdays and reduced productivity. As a result, pharmaceutical companies have invested heavily in research and development efforts to create CGRP inhibitors, which have shown remarkable efficacy in reducing the frequency and severity of migraine attacks. Furthermore, the market's growth is bolstered by the FDA approvals of various CGRP inhibitors, signaling their safety and efficacy. These approvals have paved the way for a wider adoption of CGRP inhibitors among healthcare providers and patients. As a result, the market has witnessed the launch of several branded and generic CGRP inhibitor drugs, offering a broader range of choices to patients and contributing to market expansion. Moreover, the Global CGRP Inhibitor Market is characterized by intense competition among pharmaceutical giants, with companies constantly striving to develop innovative formulations and delivery methods to improve patient outcomes. Additionally, advancements in biotechnology and neuroscience have facilitated a better understanding of the underlying mechanisms of migraine, leading to the development of more targeted and effective CGRP inhibitors.
Key Market Drivers
Rising Prevalence of Migraines and Cluster Headaches
The Global CGRP (Calcitonin Gene-Related Peptide) Inhibitor Market has witnessed a significant boost in recent years, largely attributable to the rising prevalence of migraines and cluster headaches worldwide. Migraines, characterized by intense and debilitating headaches often accompanied by nausea, vomiting, and sensitivity to light and sound, affect an ever-increasing number of individuals globally. Similarly, cluster headaches, though less common, are excruciatingly painful and tend to occur in clusters or cycles, affecting individuals' quality of life .In June 2023, during Migraine and Headache Awareness Month, the foundation introduced the "GET HEADUCATED" campaign to emphasize the importance of educating individuals and communities about the disorder. This initiative aims to mobilize the community in addressing stigma associated with the condition while fostering greater awareness, ultimately driving the adoption of treatment options.
The sheer magnitude of these disorders' impact on individuals, both in terms of physical suffering and the socioeconomic burden they impose, has prompted a growing demand for more effective treatment options. Traditional remedies, including over-the-counter pain relievers and preventive medications, often provide limited relief and are associated with various side effects, leaving patients and healthcare providers seeking alternative solutions. CGRP inhibitors have emerged as a ray of hope in this landscape, as they address the root causes of migraines and cluster headaches, offering more effective and well-tolerated treatment options.
The rising prevalence of migraines and cluster headaches has not only increased the patient pool but has also garnered attention from the pharmaceutical industry. Recognizing the immense unmet medical need and the potential market opportunity, pharmaceutical companies have ramped up their research and development efforts to create innovative CGRP inhibitor formulations. This surge in investment has resulted in the development of a diverse range of CGRP inhibitors, including monoclonal antibodies and small molecules, each designed to cater to the specific needs of patients.
Moreover, the heightened awareness of migraine and cluster headache disorders, fueled by patient advocacy groups and healthcare campaigns, has further accelerated diagnosis and treatment initiation. Patients are more informed about their condition, and healthcare providers are increasingly recognizing the potential benefits of CGRP inhibitors in providing effective and sustainable relief.
Key Market Challenges
High Treatment Costs and Accessibility Issues
CGRP inhibitors are at the forefront of migraine and cluster headache treatments due to their efficacy and novel mechanisms of action. However, their development involves extensive research, clinical trials, and biotechnological processes, making them expensive to produce. As a result, the price tag attached to CGRP inhibitors is often exceptionally high, putting them out of reach for many patients. Even when patients recognize the potential benefits of CGRP inhibitors, many face insurmountable challenges when seeking insurance coverage or reimbursement for these treatments. Insurance companies and healthcare payers may be hesitant to cover the cost of CGRP inhibitors due to their high price, requiring substantial evidence of cost-effectiveness and long-term safety. This reluctance can limit patient access, leaving them to shoulder the financial burden themselves.
The accessibility issues are further exacerbated in developing regions where healthcare infrastructure may be lacking, and patients may not have the financial means to afford these costly treatments. This disparity in access to CGRP inhibitors underscores a global healthcare divide, leaving many individuals without access to cutting-edge migraine and cluster headache therapies. High treatment costs can not only deter patients from starting CGRP inhibitor therapies but also lead to non-adherence, as some patients may ration or skip doses to make their medication last longer. This compromises the effectiveness of the treatment and may contribute to suboptimal outcomes.
Key Market Trends
Emerging Biosimilars and Generics
Emerging biosimilars and generics are playing a pivotal role in boosting the Global CGRP (Calcitonin Gene-Related Peptide) Inhibitor Market. These cost-effective alternatives to branded CGRP inhibitors are reshaping the treatment landscape for migraine and cluster headache sufferers.
Biosimilars, which are biologic drugs similar to the original CGRP inhibitors, offer comparable efficacy and safety profiles at a reduced cost. They are gaining traction in the market as patents for some branded CGRP inhibitors expire. Biosimilars present a win-win situation, allowing patients to access CGRP inhibitor therapies at more affordable prices while increasing market competitiveness. Generics, on the other hand, are non-branded versions of the original CGRP inhibitors. As patents expire, generic versions become available, offering a more budget-friendly option for patients. This trend is particularly significant in healthcare systems where cost considerations heavily influence treatment decisions.
The emergence of biosimilars and generics addresses the issue of treatment affordability and accessibility, breaking down barriers that once hindered patient access to CGRP inhibitors. As competition increases, the prices of these medications are likely to decrease, making CGRP inhibitor therapies available to a broader patient population, including those with limited insurance coverage or residing in regions with constrained healthcare resources. Moreover, the presence of biosimilars and generics encourages pharmaceutical companies to stay competitive by continuously improving their products and services. This competitive environment can drive innovation and lead to the development of more efficient and cost-effective CGRP inhibitor therapies.
In this report, the Global CGRP Inhibitor Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
Company Profiles: Detailed analysis of the major companies present in the Global CGRP Inhibitor Market.
Global CGRP Inhibitor Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report: